Theravance Biopharma announced it will wind down its R&D organization and cut roughly 50% of its workforce after a Phase 3 failure for ampreloxetine, its experimental candidate. The company said the decision follows repeated clinical setbacks and will focus remaining resources on commercial activities and near‑term assets. The move highlights a broader industry pattern of belt‑tightening after late‑stage failures: companies increasingly pivot to preserve cash and maximize value from approved or late‑stage products while outsourcing or licensing early discovery work.